The Seizures drugs in development market research report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Seizures. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Seizures - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Seizures and features dormant and discontinued products.

GlobalData tracks 81 drugs in development for Seizures by 73 companies/universities/institutes. The top development phase for Seizures is preclinical with 35 drugs in that stage. The Seizures pipeline has 72 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Seizures pipeline products market are: UCB, Jazz Pharmaceuticals and Ovid Therapeutics.

The key targets in the Seizures pipeline products market include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR), Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).

The key mechanisms of action in the Seizures pipeline product include Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR) Agonist with 12 drugs in Pre-Registration. The Seizures pipeline products include ten routes of administration with the top ROA being Oral and five key molecule types in the Seizures pipeline products market including Small Molecule, and Gene Therapy.

Seizures overview

A seizure is a medical condition where the patient has a temporary, unstoppable surge of electrical brain activity. Affected brain cells uncontrollably fire signals to others around them, overloading the affected areas of the brain. That overload can cause a wide range of symptoms or effects, including abnormal sensations, passing out, and uncontrolled muscle movements. Up to 11% of people in the US will have at least one seizure during their life. Epilepsy is much less common: Between 1% and 3% of people in the US will develop epilepsy during their lifetime. Treatments for seizures vary widely, because the treatment for a provoked seizure depends almost entirely on its cause. Antiepileptic drugs are often the first treatment option for people experiencing multiple seizures. They target the signaling activities in specific brain cells and can effectively control seizures in approximately 70% of cases.

For a complete picture of Seizures’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.